Key Highlights

● TCGX Acquisition Corp. II filed an S-1 for a proposed $100 million IPO of 10 million Class A shares at $10.00 each.

● The blank-check company targets healthcare, life sciences and medical technology firms, with interest in Asia-based assets.

● TCG Crossover Fund III committed a forward purchase of at least $20 million to close alongside any Business combination.

● The company has 24 months from IPO closing to complete a deal, extendable with Shareholder approval.

TCGX Acquisition Corp. II filed an S-1 registration statement on September 25, 2026 for a proposed $100 million initial public offering of 10 million Class A ordinary shares at $10.00 each, intending to list on Nasdaq under the ticker TCXB. The blank-check company is sponsored by TCGX Sponsor II, LLC, an affiliate of TCG Crossover Management LLC, and is aimed squarely at healthcare, life sciences and medical technology targets.

Healthcare Focus, With An Eye On Asia

The S-1 describes TCGX Acquisition Corp. II as seeking companies in healthcare and healthcare-related industries where its management team's investing experience gives it an edge, and notes potential interest in Asia-based assets, including opportunities in Hong Kong and mainland China. The Underwriting discount is structured as 1% payable at closing (about $1 million) plus a 3% deferred fee (about $3 million) contingent on completing a business combination.

Leadership And Sponsor Ties

Chen Yu, M.D., M.B.A., is named chief executive officer; the filing describes him as the founder of TCGX with more than 20 years of healthcare investing experience. Craig Skaling is named chief financial officer, with a background described as more than 25 years in finance and operations.

Independent directors slated to join post-IPO include Joshua Cohen, co-CEO of Amylyx; Mark McKenna, a healthcare executive; and Michael Henderson, M.D., who the filing says has biotech chief-executive experience. The sponsor purchased 2.5 million founder shares for approximately $25,000, plus 450,000 private-placement shares at $10.00 each, structured to preserve 20% sponsor ownership after the IPO.

Trust Account, Timeline And Forward Purchase Backstop

The full $100 million in IPO proceeds is slated for deposit into a trust account administered by Odyssey Transfer and Trust Company. The filing gives the company 24 months from the closing of the offering to complete an initial business combination, extendable by shareholder approval.

Notably, the S-1 discloses a forward purchase agreement under which TCG Crossover Fund III has committed to purchase at least $20 million, or 2 million shares, to close concurrently with any eventual business combination, a backstop mechanism meant to help fund a deal even if public shareholders redeem heavily.

What This Filing Is, And Isn't

As an S-1, this filing registers securities for sale but does not itself constitute a completed IPO; TCGX Acquisition Corp. II has no operating business, Revenue or identified acquisition target. The filing does not disclose an expected pricing date or the identity of the underwriters running the book beyond referencing standard SPAC mechanics. Investors should treat every dollar figure, the $100 million raise, the $25,000 founder-share purchase, the $20 million forward commitment, as proposed terms subject to change before the registration statement is declared effective and the deal actually prices.

The TCG Crossover Track Record Behind The Filing

TCGX Acquisition Corp. II is the second such vehicle sponsored by affiliates of TCG Crossover, a healthcare-focused Investment firm. The S-1 leans on that lineage, presenting Chen Yu's tenure founding TCGX and the broader team's healthcare-investing background as the rationale for why target companies and their shareholders should prefer a combination with this SPAC over other paths to going public, such as a traditional IPO or a direct listing. The filing does not, however, disclose the performance or outcome of any prior TCG Crossover-sponsored SPAC, so investors cannot use this document alone to assess a historical track record.

Conditions Still Standing Between Filing And Listing

SEC review of the S-1 must conclude, and the registration statement must be declared effective, before shares can be sold to the public. The 24-month deadline to complete a business combination begins running only once the IPO actually closes. The TCG Crossover Fund III forward purchase agreement, sized at a minimum $20 million, is contingent on an eventual business combination closing. No specific healthcare, life sciences or MedTech target has been named in the filing.